Gene Therapy Shield for Cancer Treatment
Gene therapy could be used to shield important healthy stem cells of cancer patients during radiotherapy, enabling stronger doses to be administered safely, according to a report published today in the Journal of Gene Medicine*.
Bone Marrow Cells Can Become Functional Gut Lining Cells
Researchers report the discovery that cells used in bone marrow transplantation can develop into new cells lining the gut, according to a study by Yale School of Medicine in the Proceedings of the National Academy of Sciences.
Tissue Engineering Technique Does Not Cause Tumor Growth
A gene therapy approach used in creating new arteries for older patients does not appear to cause cancer, according to a pilot study by Yale School of Medicine researchers reported in the Proceedings of the National Academy of Sciences.
Stem Cell Mobilization Therapy Ineffective in Repairing Heart Attack Damage
Therapy that involved bone marrow stem cells did not improve cardiac function in patients following a heart attack, according to a study in the March 1 issue of JAMA.
FDA Approves Rituxan(R) – The First Targeted B-Cell Therapy for Treatment of Moderate-to-Severe Rheumatoid Arthritis
Genentech, Inc. (NYSE: DNA – News) and Biogen Idec, Inc. (Nasdaq: BIIB – News) announced today that the U.S. Food and Drug Administration (FDA) has approved, following Priority Review, the therapeutic antibody Rituxan® (Rituximab) in combination with methotrexate (MTX) to reduce signs and symptoms in adult patients with moderately-to-severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
Bioengineers Create Stable Networks Of Blood Vessels
Yale biomedical engineers have created an implantable system that can form and stabilize a functional network of fine blood vessels critical for supporting tissues in the body, according to a report in the Proceedings of the National Academy of Sciences.
ABSTRACT, REVIEWS, & SPECIAL REPORTS
Human Embryonic Stem Cells and Their Differentiated Derivatives Are Less Susceptible to Immune Rejection Than Adult Cells
Thus, immunosuppressive regimens for hESC-based therapeutics could be highly reduced compared with conventional organ transplantation because direct allorejection processes of hESCs and their derivatives are considerably weaker.
Innovation in Biomedicine: Can Stem Cell Research Lead the Way to Affordability?
In 2004, California voters approved a US$3 billion stem cell research program. Goozner outlines his innovative suggestions for ensuring that any treatments resulting from the program will be made affordable for state residents.